A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results
- Publication date
- Publisher
- 'American Society of Clinical Oncology (ASCO)'